LOGIN  |  REGISTER
Recursion
Astria Therapeutics

Ginkgo Bioworks Announces Date of Second Quarter 2023 Results Presentation

August 02, 2023 | Last Trade: US$7.85 0.24 -2.97
  • Presentation and Q&A session scheduled for post-market on Wednesday, August 9, 2023

BOSTON, Aug. 2, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, beginning at 5:30 p.m. ET.

The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.

To ask a question ahead of the presentation, please submit them to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it..

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it. 

MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page